Munafa Stock Market Course + Intraday & FNO calls 
EDIT NEWS why is Editas Medicine, Inc. price falling or rising
EDIT NEWS reasons for why stock price of Editas Medicine, Inc. is falling or rising
EDIT Editas Medicine is falling or rising technical reasons
Technical analysis forecast of Editas Medicine Stock is that its in a uptrend for shortterm, and I will avoid taking a SHORT or SELL trade in this stock. Look for opportunities to BUY or go LONG in Editas Medicine EDIT at this time. Stock is rising and might rise more.
It appears as if Editas Medicine EDIT gave a large move recently.
Stock of Editas Medicine (EDIT) is trading above an important moving average line, but it crossed this line recently, which means that it could show a small or a large fall soon enough depending on its trend.
EDIT Editas Medicine is falling or rising NEWS fundamental reasons
Central Bank of India posts 30% credit growth at Rs 3.81 lakh cr in Q2 Central Bank of India reported a significant 30 percent credit growth for the second quarter of this financial year. The total advances reached Rs 2.93 lakh crore as of September 30, 2025. Total deposits increased by 14 percent, amounting to Rs 5.08 lakh c - NEWS as on 2026-10-05 indiatimes.com
Bank of India Credit Risk among top 5 mutual funds that beat fixed deposits in 3 years with over 10% gains Debt funds whose returns are more than a conventional fixed deposit instrument. - NEWS as on 2026-10-03 indiatimes.com
US Market: AI credit surge tests lenders as future revenues remain uncertain AI-related borrowing has surged substantially in low-rated U.S. firms this year, prompting investor scrutiny of financial assumptions. Lenders are seeking higher returns and greater compensation for the risks associated with these investments. While there - NEWS as on 2026-10-01 indiatimes.com
Healthier balance sheets drive credit upgrades across sectors in H1FY27 Credit ratios improved across rating agencies as lower leverage and healthy liquidity supported firms, though crude prices, inflation and US tariff uncertainty pose risks - NEWS as on 2026-09-30 business-standard.com
Gujarat Themis secures million private credit for Japanese acquisition Founded in 1981, Gujarat Themis is India's first company to start commercial production of the anti-tuberculosis drug Rifampicin, according to its website - NEWS as on 2026-09-29 business-standard.com
Bank deposits, credit shrink in fortnight to September 15 Outstanding bank deposits and advances declined significantly during the fortnight ending September 15. Deposits fell by Rs 2.49 lakh crore due to the maturing of high-cost bulk deposits. Deposit growth slowed to 17.3%, while credit growth also dropped to - NEWS as on 2026-09-25 indiatimes.com
Credit card spends fall 2.8% to ?2.02 trillion in August, shows RBI data Credit card spending fell to Rs 2.02 trillion in August as online spends declined 7 per cent, while the number of outstanding cards rose to 124.05 million - NEWS as on 2026-09-24 business-standard.com
Banks likely to deploy FCNR(B) liquidity in coming months as festive credit demand rises: RBI Deputy Guv Reserve Bank Deputy Governor Rohit Jain stated that banks are expected to deploy additional liquidity from FCNR(B) deposits. This deployment is likely driven by anticipated strong credit demand during the festive season. The RBI will not direct banks towar - NEWS as on 2026-09-24 indiatimes.com
UPI MDR from Oct 15: Should you switch from UPI to debit or credit cards? Before switching to cards, users should understand which UPI payments attract MDR and who actually bears the cost. - NEWS as on 2026-09-23 business-standard.com
Crisil Rating assigns 'AA-/A1+' rating to credit facilities of SG Finserve SG Finserve said that Crisil Rating has assigned its 'Crisil AA-/Stable/Crisil A1+' ratings to the bank facilities of the company. - NEWS as on 2026-09-22 business-standard.com
The rise of asset-backed borrowing in India's credit ecosystem Asset-backed borrowing is gaining traction in India's credit market, particularly through gold-backed lending, which provides essential liquidity without needing to sell investments immediately. The rise of digital platforms is making these services more a - NEWS as on 2026-09-21 indiatimes.com
More announcements and NEWS
EDIT Editas Medicine, Inc. current price & indicator signals
Recent prices of EDIT Editas Medicine, Inc. are as follows: Daily volume is divided by 10 day averaged volume
| Date | Close | Range | Change % | Volume |
| 05 Mon Oct 2026 | 2.80 | 2.56 to 2.81 | 6.87% | 1.05 times |
| 02 Fri Oct 2026 | 2.62 | 2.51 to 2.63 | 3.97% | 0.9 times |
| 01 Thu Oct 2026 | 2.52 | 2.52 to 2.62 | -1.95% | 0.64 times |
| 30 Wed Sep 2026 | 2.57 | 2.55 to 2.72 | -0.77% | 0.68 times |
| 29 Tue Sep 2026 | 2.59 | 2.51 to 2.62 | 3.19% | 0.65 times |
| 28 Mon Sep 2026 | 2.51 | 2.42 to 2.55 | -3.09% | 0.92 times |
| 25 Fri Sep 2026 | 2.59 | 2.57 to 2.80 | -5.82% | 1.12 times |
| 24 Thu Sep 2026 | 2.75 | 2.55 to 2.76 | 2.23% | 0.94 times |
| 23 Wed Sep 2026 | 2.69 | 2.67 to 3.14 | -7.88% | 2.15 times |
| 22 Tue Sep 2026 | 2.92 | 2.81 to 2.93 | 3.18% | 0.96 times |
| 21 Mon Sep 2026 | 2.83 | 2.70 to 2.89 | 4.81% | 1.04 times |
| 18 Fri Sep 2026 | 2.70 | 2.68 to 2.83 | -0.74% | 7.1 times |
Videos related to: EDIT NEWS why is Editas Medicine, Inc. price falling or rising
Hindi Basics How To Trade In FnO Futures Options Stock Market
- NASDAQ Screeners
- NASDAQ Daily Screener
- NASDAQ Weekly Screener
- NASDAQ Monthly Screener
- Support & Resistance
- NASDAQ Shares Near Support
- NASDAQ Shares Near Resistance
